Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Amarantus Bioscience Holdings, Inc. | v411155_ex99-1.htm |
| EX-99.2 - EXHIBIT 99.2 - Amarantus Bioscience Holdings, Inc. | v411155_ex99-2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55016 | 26-0690857 |
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(IRS Employer |
|
655 Montgomery Street, Suite
900 |
94111 |
| (Address of Principal Executive Offices) | (Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On May 20, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2015 and other matters described in the press release. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
| Item 8.01 | Other Items. |
On May 19, 2015, the Company issued a press release announcing that it will be presenting at two upcoming conferences. A copy of the Company’s press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Amarantus Bioscience Holdings, Inc. Press Release, dated May 20, 2015. | |
| 99.2 | Amarantus Bioscience Holdings, Inc. Press Release, dated May 19, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | ||||
| Date: May 20, 2015 | By: | /s/ Gerald E. Commissiong | ||
| Name: Gerald E. Commissiong | ||||
| Title: Chief Executive Officer | ||||